146 related articles for article (PubMed ID: 8623464)
41. Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts.
Masri MA
Transplant Proc; 1995 Feb; 27(1):366. PubMed ID: 7533412
[No Abstract] [Full Text] [Related]
42. Topical cyclosporine administration in rabbits.
Stokar LM; Burckart GJ; D'Souza M; Cohen B; Venkataramanan R
Res Commun Chem Pathol Pharmacol; 1990 Apr; 68(1):117-20. PubMed ID: 2345801
[TBL] [Abstract][Full Text] [Related]
43. Rescue therapy with rapamycin blocks an ongoing process of heart allograft rejection.
Ferraresso M; Wang ME; Stepkowski SM; Kahan BD
Transplant Proc; 1993 Feb; 25(1 Pt 1):729. PubMed ID: 8438460
[No Abstract] [Full Text] [Related]
44. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis.
Morris RE; Huang X; Gregory CR; Billingham ME; Rowan R; Shorthouse R; Berry GJ
Transplant Proc; 1995 Jun; 27(3):2068-9. PubMed ID: 7792888
[No Abstract] [Full Text] [Related]
45. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival.
Dane KY; Nembrini C; Tomei AA; Eby JK; O'Neil CP; Velluto D; Swartz MA; Inverardi L; Hubbell JA
J Control Release; 2011 Dec; 156(2):154-60. PubMed ID: 21864593
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of skin graft rejection in mice by rapamycin: a novel immunosuppressive macrolide.
Eng CP; Gullo-Brown J; Chang JY; Sehgal SN
Transplant Proc; 1991 Feb; 23(1 Pt 1):868-9. PubMed ID: 1990708
[No Abstract] [Full Text] [Related]
47. Long-term survival of limb allografts after weaning of cyclosporine: possible role of microchimerism.
Durlik M; Lukomska B; Namysłowski A; Janczewska S; Cybulska E; Olszewski WL
Transplant Proc; 1997; 29(1-2):1226-7. PubMed ID: 9123285
[No Abstract] [Full Text] [Related]
48. Difficulty in the induction of tolerance to vascularised skin allografts.
Lim SM; Li SQ; Poh LH; Chong TW
Transplant Proc; 1994 Aug; 26(4):1957. PubMed ID: 8066633
[No Abstract] [Full Text] [Related]
49. Withdrawal of immunosuppression: implications for composite tissue allograft transplantation.
Hricik DE
Transplant Proc; 1998 Sep; 30(6):2721-3. PubMed ID: 9745554
[TBL] [Abstract][Full Text] [Related]
50. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine.
Schorlemmer HU; Ruuth E; Kurrle R
Transpl Int; 1998; 11 Suppl 1():S340-4. PubMed ID: 9665012
[TBL] [Abstract][Full Text] [Related]
51. Determination of the suppression of the cellular immune response of mice with donor-specific gamma globulin during chimeric state.
Kende M
Prog Clin Biol Res; 1984; 161():77-89. PubMed ID: 6207548
[TBL] [Abstract][Full Text] [Related]
52. Site-specific suppression of cell-mediated immunity by cyclosporine.
Black KS; Nguyen DK; Proctor CM; Patel MP; Hewitt CW
J Invest Dermatol; 1990 May; 94(5):644-8. PubMed ID: 2324520
[TBL] [Abstract][Full Text] [Related]
53. Gangliosides potentiate the immunosuppressive effects of cyclosporin A in rat skin allografts.
Sconocchia G; Ausiello CM; Spagnoli GC; Sciortino G; Filinger V; Giudiceandrea F; Cervelli V; Adorno D; Casciani CU
Transpl Int; 1992; 5 Suppl 1():S544-6. PubMed ID: 14621872
[TBL] [Abstract][Full Text] [Related]
54. Mechanisms of site-specific immunosuppression.
Black KS; Patel MP; Patel AP; Llull R; Ebojo M; Nguyen T; Hewitt CW
Transplant Proc; 1991 Feb; 23(1 Pt 1):120-1. PubMed ID: 1990494
[No Abstract] [Full Text] [Related]
55. Importance of schedule of administration of adjunctive, short-term immunosuppression in ALS- and bone marrow cell-treated, skin-allografted mice.
Gozzo JJ; Plowey J; Hartner WC; De Fazio SR
Transplant Proc; 1995 Feb; 27(1):169-70. PubMed ID: 7878958
[No Abstract] [Full Text] [Related]
56. Site-specific immune suppression with topical cyclosporine. Synergism with combined topical corticosteroid added during the maintenance phase.
Llull R; Lee TP; Vu AN; Black KS; Hewitt CW
Transplantation; 1995 May; 59(10):1483-5. PubMed ID: 7770938
[No Abstract] [Full Text] [Related]
57. A comparative approach to topical cyclosporine therapy.
Williams DL
Eye (Lond); 1997; 11 ( Pt 4)():453-64. PubMed ID: 9425407
[TBL] [Abstract][Full Text] [Related]
58. Sustained suppression of xenoreactive natural antibodies: anti-IgM monoclonal antibody and anti-B cell immunosuppressants.
Van der Werf WJ; Blakely ML; Hancock W; Soares M; Latinne D; Bazin H; Bach FH
Transplant Proc; 1994 Jun; 26(3):1372-3. PubMed ID: 8029945
[No Abstract] [Full Text] [Related]
59. The role of hyperimmune alloantiserum in allograft survival.
Oluwasanmi JO
Immunology; 1973 Nov; 25(5):881-9. PubMed ID: 4586741
[TBL] [Abstract][Full Text] [Related]
60. Use of pharmacologic immunosuppression to augment the specific unresponsiveness (tolerance) to skin allografts induced by donor-specific bone marrow in antilymphocyte serum-treated mice: the unique effect of sirolimus.
Hale D; Gottschalk R; Maki T; Monaco AP
Transplant Proc; 1998 Aug; 30(5):2432-4. PubMed ID: 9723527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
